Biotech and Pharma Dealmaking in the Era of Uncertainty

ABOUT	SPEAKERS	BENEFITS	REGISTER

LAST CHANCE - REGISTER NOW

Large and mid-sized pharma are now biotech’s primary sources of financing source — and virtually their only exit opportunities. Already we’re seeing the effects of the shift in power in deal structure and price as many biotechs chase a smaller pool of buyers. Meanwhile, those buyers are hardly a homogeneous group – pursuing very different strategies, with some Big Pharmas far more aggressively interested in dealmaking than others, who are preoccupied with less R&D-intensive strategies. In this webinar, we’ll review …

Some key deal comparables, showing the important structural and financial trends within this buyer’s market

The different Big Pharma strategies and how they’re affecting biotech dealmaking appetites

The challenges for investors, in particular venture capitalists, in providing ongoing financing

The discussion will be delivered in a convenient audio conference format, and capped off with an interactive Q&A round.

So join us, in the convenience of your own office, for a thought-provoking analysis. Grab your team (or several teams), a conference room at your office, a phone and a computer with Web access (that last one's optional). No travel required.

Back to top

SPEAKERS

ROGER LONGMAN is Managing Partner - Pharma at Elsevier Business Intelligence. He has been involved with the health care industry for more than 20 years.

In 1983, Mr. Longman joined The Wilkerson Group as a writer covering the pharmaceutical and biotech industries for IN VIVO: The Business & Medicine Report. In 1989, Mr. Longman along with David Cassak led a buyout of the Wilkerson Group's publications division, which they moved to Connecticut and renamed Windhover Information Inc.

Since then Mr. Longman and Mr. Cassak have launched several new ventures including

Start-Up: Emerging Medical Ventures™
Strategic Transactions database, the industry’s most comprehensive and detailed database of industry M&A, alliances and financings
The RPM Report: Regulation • Policy • Market Access™, an analysis of key marketing, strategy and R&D implications of the changes in Washington at CMS and FDA
A series of senior-executive conferences in corporate strategy, business development, R&D, and finance.

In 2004, Windhover acquired Medtech Insight, an information company covering the medical device field through a market-leading newsletter, a series of in-depth market reports, and a number of conferences. In 2008, Windhover was acquired by Reed Elsevier and merged with Elsevier's FDC Reports into the new Elsevier Business Intelligence.

At Elsevier, Mr. Longman runs the pharma business unit that features several leading publications serving biopharma executives, including IN VIVO, Start-Up, The RPM Report, “The Pink Sheet,” “Pink Sheet Daily”and PharmAsia News, among others. In addition, Elsevier produces a number of prominent biopharmaceutical conferences and partnering events, as well as biopharmaceutical content in Strategic Transactions and Inteleos databases

Over the years, Mr. Longman has become recognized as one of the leading experts in biopharmaceutical strategy and dealmaking. He is often asked to speak at many key industry events organized by important trade organizations like the Biotechnology Industry Organization (BIO), investment banks, venture capital firms and leading pharma and biotech companies. He lectures regularly at several leading universities. Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.

Back to top

BENEFITS

What does registration get me?

One (1) phone line, for you alone, or around which to gather your team(s). Toll-free in the U.S. only.
One (1) password to a website on which you'll be taken through the presenters' slides as they speak to them.
An interactive Q&A round with speakers by phone and electronic submission
Online access to the audio and slides of the entire event if you can't attend the webinar live, and still want to hear the content.
The insight you've come to expect and respect from Windhover Webinars and our guest speakers.

What are the unique benefits of a webinar?

Convenience – and lower cost. Your entire team can listen in one room. No travel required!
A team approach. You've often wanted to have everyone on your team getting the same knowledge and insight you derive from physical conferences. Now you can.
Interactivity. You're remote, but not removed. Our webinars let you ask the important, burning, controversial questions of our speakers that you'd be able to pose at a physical conference.
Flexibility. Want to be able to review what you learn? No problem ... just register for the live webinar PLUS a digital copy of the entire event to listen to at your convenience. Interested in the topic but have a scheduling conflict? Don't worry — the recording is available for purchase at any time!

Back to top

REGISTER

Register for the live webinar, the live webinar PLUS the audio recording or the audio recording only!

Live webinar: $299
Live webinar plus complete audio recording: $399
Audio recording only: $399

Register online: Click here for the live webinar

Register online: Click here for the live webinar PLUS recording

Buy the recording: Click here for just the recorded webinar

Register by email: custcare@elsevier.com

Register by phone: 1 (800) 332-2181 (U.S.) / +1 (908) 547-2159 (non- U.S.)

Back to top
_______________________________________________________

Webinar presented by

Windhover Webinars
Elsevier Business Intelligence
P.O. Box 7247
Philadelphia, PA 19101-9257
* Tel: +1 (800) 332-2181 (U.S.)
or +1 (908) 547-2159 (non-U.S.)
* Fax: +1 (908) 547-2165